NEW YORK and VIENNA, Austria, Feb. 13, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing…
Immunocompromised Individuals, Including Organ Transplant Recipients, Are at Increased Risk of Severe COVID-19 and Poor Clinical Outcomes SARS-CoV-2 has Mutated…
Clinical trials for testing potential drugs, procedures, or devices have evolved over hundreds of years. Scientists use clinical trials on…
BOSTON, MASSACHUSETTS, Feb. 06, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing…
LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete assay receives Emergency Use Authorization from the FDA along with being successfully…
WARMINSTER, Pa., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive…
PALO ALTO, Calif., Feb. 04, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento…
SAN DIEGO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today distributed dividend confirmation statements to…
WALTHAM, Mass., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical stage biopharmaceutical company on a mission…
Development expected to capitalize upon tumor targeting Quatramers™ MUC1-C could be effective against a number of drug resistant cancers such…